The legal landscape — 2026
In most of the world, the classic psychedelics remain strictly controlled — Schedule I in the United States, meaning "no accepted medical use." But the map is being redrawn faster than at any time since the 1960s.
Three things are happening at once. First, medicine: several psilocybin and LSD therapies are moving through late-stage FDA trials, and in 2026 regulators granted priority reviews to fast-track them. Second, local reform: a growing number of U.S. cities and states have decriminalized or opened supervised-use programs. Third, federal signal: an April 2026 executive order moved to accelerate access for serious mental illness — the first time a psychedelic compound has been fast-tracked this way. None of this changes the underlying Schedule I status, and the picture differs in every jurisdiction. Metanoia is a research and education nonprofit; we do not supply any substance, and nothing here is legal advice.
The harder question: who do these belong to?
Almost everything modern science "discovered" about psychedelics was known to Indigenous peoples for centuries, even millennia. That history carries a debt — and the field's record of repaying it is poor.
The shadow of María Sabina
A cautionary taleWhen the Mazatec healer María Sabina let an American visitor witness her mushroom ceremony in 1955, and he published it in Life magazine, her village was overrun with seekers. Her community denounced her for revealing the sacred; her house was burned; she died in poverty. Researchers call it a "representational hangover" — reducing a whole people to a proxy for a drug. It is the reason any serious psychedelic organization must build in reciprocity, credit, and respect for the source, rather than simply extracting from it.
Peyote — a plant, a right, and a limit
Do not touchThe peyote cactus is the clearest ethical line in the whole field. It is slow-growing and now listed as vulnerable, threatened by over-harvest and habitat loss. In U.S. law it is protected specifically for the Native American Church. And when broad decriminalization movements arose, Indigenous leaders asked that peyote be excluded — to protect both the plant and their exclusive religious right to it. Even synthetic mescaline is rejected by some practitioners as a violation of the cactus's sacredness. The lesson is humbling: sometimes the right ethical answer is to leave something alone.
Why Metanoia chose mushrooms
This is not an arbitrary starting point. Psilocybin mushrooms are, in a real sense, the most ethical substrate for a scalable "whole organism" research program — precisely because they lack peyote's problems. They grow fast and are easily cultivated, so research never depends on stripping wild populations. They are not endangered. And while the Mazatec and other peoples deserve full respect and credit as the source of this knowledge, there is no single community holding exclusive religious rights that broad study would violate.
That shapes a simple sourcing principle we hold across the family: prefer cultivable, sustainable sources over threatened or wild ones — mushrooms and fast-growing San Pedro cactus over slow-growing peyote; and, where the science supports it, pure or lab-grown compounds over harvesting a threatened animal, as with the 5-MeO-DMT toad. Honoring the source without appropriating it is not a footnote to the science. For us, it is a condition of doing the work at all.